Archives to Collect Info on Radiation Exposure Worldwide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

SPOKANE, Wash-A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

SPOKANE, Wash—A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

The Radiation Health Effects Archives, located on the campus of Gonzaga University, will continue and expand the collection of the Hanford Health Information Archives, founded last year to collect information about the experiences of people who lived in the region around the Hanford, Washington, nuclear facility between 1944 and 1972. These individuals are sometimes referred to as “Hanford downwinders.”

The Hanford-exposure area includes Eastern Washington, northeastern Oregon, and much of Idaho, plus areas along the Columbia River downstream from Hanford. The facility’s airborne emissions were also carried by the wind into parts of Montana and Canada.

The Archives have processed more than 400 donations with information from more than 1,100 downwinders. People have donated medical records, oral histories, journals, yearbooks, photographs, and other items that help describe their lifestyles and diets, as well as their health, from the mid-1940s to the present.

The data are available online at http://www.foley.gonzaga.edu/hhiahome.html. Comments and questions can be sent via e-mail to hhia@foley.gonzaga.edu.

Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content